CV Sciences Inc
CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements, hemp-based cannabidiol (CBD), and plant based food products in North America. It offers its products under the PlusCBD, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributor… Read more
CV Sciences Inc (CVSI) - Net Assets
Latest net assets as of September 2025: $1.54 Million USD
Based on the latest financial reports, CV Sciences Inc (CVSI) has net assets worth $1.54 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.00 Million) and total liabilities ($5.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.54 Million |
| % of Total Assets | 22.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | -83.99% |
| 10-Year Change | -92.29% |
| Growth Volatility | 75.89 |
CV Sciences Inc - Net Assets Trend (2012–2024)
This chart illustrates how CV Sciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CV Sciences Inc (2012–2024)
The table below shows the annual net assets of CV Sciences Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.79 Million | -38.17% |
| 2023-12-31 | $2.90 Million | +473.62% |
| 2022-12-31 | $-777.00K | -121.93% |
| 2021-12-31 | $3.54 Million | -68.40% |
| 2020-12-31 | $11.21 Million | -61.53% |
| 2019-12-31 | $29.15 Million | -3.22% |
| 2018-12-31 | $30.12 Million | +83.84% |
| 2017-12-31 | $16.38 Million | +24.03% |
| 2016-12-31 | $13.21 Million | -43.28% |
| 2015-12-31 | $23.29 Million | +10.49% |
| 2014-12-31 | $21.07 Million | +153.70% |
| 2013-12-31 | $8.31 Million | -- |
| 2012-12-31 | $0.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to CV Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8698100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $88.78 Million | 4945.74% |
| Total Equity | $1.79 Million | 100.00% |
CV Sciences Inc Competitors by Market Cap
The table below lists competitors of CV Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sunshine Biopharma Inc
NASDAQ:SBFM
|
$5.06 Million |
|
Dien Quang JSC
VN:DQC
|
$5.06 Million |
|
FEEDBACK PLC LS-5
F:GZM0
|
$5.06 Million |
|
DILLARDS-A
BE:DL7A
|
$5.06 Million |
|
SA Corporate Real Estate Fund Managers Ltd
JSE:SAC
|
$5.05 Million |
|
Peregrine Gold Ltd
AU:PGD
|
$5.05 Million |
|
Silla Sg Co. Ltd
KQ:025870
|
$5.05 Million |
|
Moatech Co. Ltd
KQ:033200
|
$5.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CV Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,903,000 to 1,795,000, a change of -1,108,000 (-38.2%).
- Net loss of 2,394,000 reduced equity.
- Other factors increased equity by 1,286,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.39 Million | -133.37% |
| Other Changes | $1.29 Million | +71.64% |
| Total Change | $- | -38.17% |
Book Value vs Market Value Analysis
This analysis compares CV Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.17x to 3.08x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.18 | $0.03 | x |
| 2018-12-31 | $0.32 | $0.03 | x |
| 2019-12-31 | $0.29 | $0.03 | x |
| 2020-12-31 | $0.11 | $0.03 | x |
| 2021-12-31 | $0.03 | $0.03 | x |
| 2022-12-31 | $-0.01 | $0.03 | x |
| 2023-12-31 | $0.02 | $0.03 | x |
| 2024-12-31 | $0.01 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CV Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -133.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.24%
- • Asset Turnover: 1.98x
- • Equity Multiplier: 4.42x
- Recent ROE (-133.37%) is below the historical average (-80.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -6.23% | -12.87% | 0.47x | 1.03x | $-3.42 Million |
| 2015 | -52.53% | -106.10% | 0.42x | 1.17x | $-14.56 Million |
| 2016 | -107.06% | -127.85% | 0.59x | 1.41x | $-15.46 Million |
| 2017 | -29.89% | -23.68% | 0.91x | 1.39x | $-6.54 Million |
| 2018 | 33.21% | 20.73% | 1.31x | 1.23x | $6.99 Million |
| 2019 | -56.99% | -30.93% | 1.02x | 1.81x | $-19.52 Million |
| 2020 | -198.75% | -91.22% | 0.80x | 2.73x | $-23.41 Million |
| 2021 | -439.01% | -77.58% | 1.11x | 5.10x | $-15.91 Million |
| 2022 | 0.00% | -50.69% | 1.27x | 0.00x | $-8.14 Million |
| 2023 | 106.85% | 19.38% | 1.74x | 3.17x | $2.81 Million |
| 2024 | -133.37% | -15.24% | 1.98x | 4.42x | $-2.57 Million |
Industry Comparison
This section compares CV Sciences Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CV Sciences Inc (CVSI) | $1.54 Million | -6.23% | 3.55x | $5.05 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |